

2/6

**MARKSANS PHARMA LIMITED**  
 Regd. Office: 21st Floor, Lotus Business Park Off. New Link Road, Andheri (West), Mumbai-400053  
**UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST MARCH 2010**

Sr. No.	PARTICULARS	For the quarter ended on		For the year ended on		Rs. in Lacs
		31.3.2010 (UNAUDITED)	31.3.2009 (UNAUDITED)	31.3.2010 (UNAUDITED)	31.3.2009 (AUDITED)	
1	Income					
a>	Net Sales/ Income from Operations	5,560.18	3,050.34	20,415.10	20,356.11	
b>	Other Operating Income	151.52	603.63	287.90	735.05	
	<b>Total Income</b>	<b>5,711.70</b>	<b>3,653.97</b>	<b>20,703.00</b>	<b>21,091.16</b>	
2	Expenditure					
a>	(Increase)/Decrease in stock in trade	(448.62)	(954.90)	1,198.19	(1,050.41)	
b>	Consumption of Material & Purchases	3,997.82	2,863.59	13,314.55	14,382.54	
c>	Employee Cost	325.01	333.56	1,140.66	1,285.74	
d>	Depreciation	245.35	256.10	983.97	972.96	
e>	Other Expenditure	537.88	2,048.80	2,080.10	3,758.39	
	<b>Total Expenditure</b>	<b>4,557.42</b>	<b>4,547.15</b>	<b>18,717.47</b>	<b>19,319.22</b>	
3	Profit from Operations before other income					
	Interest & Exceptional Items (1-2)	1,054.28	(893.18)	1,985.53	1,771.94	
4	Other Income					
5	Profit before Interest & Exceptional Item (3+4)	1,054.28	(893.18)	1,985.53	1,771.94	
6	Interest	513.28	474.70	1,929.89	1,532.86	
7	Profit after Interest but before Tax Exceptional Items	540.99	(1,367.88)	55.63	239.08	
8	Exceptional Items					
9	<b>Profit/(Loss) from Ordinary activities before Tax (7+8)</b>	<b>540.99</b>	<b>(1,367.88)</b>	<b>55.63</b>	<b>239.08</b>	
10	Tax Expenses- Current year & Deferred tax	33.50	(3.36)	33.50	189.58	
11	<b>Net Profit/(Loss) from Ordinary activities after tax(9-10)</b>	<b>507.49</b>	<b>(1,364.52)</b>	<b>22.13</b>	<b>49.50</b>	
12	Extraordinary Item					
13	<b>Net Profit (Loss) for the period (11-12)</b>	<b>507.49</b>	<b>(1,343.13)</b>	<b>22.13</b>	<b>49.50</b>	
14	Paid up Equity Share Capital (Face Value Re.1 each)	3,678.05	3,678.05	3,678.05	3,678.05	
15	Reserve Excluding Revaluation Reserve as per Balance sheet of Previous Accounting year					
16	a>- Earnings Per Share (Basic & Diluted) (before extraordinary items Rs.)	0.14	(0.37)	0.01	0.01	10,881.63
	b>- Earnings Per Share(Basic & Diluted) (after Extraordinary items- Rs.)	0.14	(0.37)	0.01	0.01	
17	Aggregate of Public Shareholding:					
	- Number of Shares	189,822,361	188,222,361	189,822,361	188,222,361	
	- Percentage of Holding	51.61%	51.17%	51.61%	51.17%	
18	Promoters and Promoter group Shareholdings	177,983,510	179,583,510	177,983,510	179,583,510	
	a>- Pledged/Encumbered	NIL	NIL	NIL	NIL	
	- Number of Shares	N/A	N/A	N/A	N/A	
	- Percentage of Holding (as a % of the total shareholding of Promoter and Promoter Group)	N/A	N/A	N/A	N/A	
	- Percentage of Holding (as a % of the total share capital of the Company)	N/A	N/A	N/A	N/A	
	a>- Non-encumbered					
	- Number of Shares	177,983,510	179,583,510	177,983,510	179,583,510	
	- Percentage of Holding (as a % of the total shareholding of Promoter and Promoter Group)	100%	100%	100%	100%	
	- Percentage of Holding (as a % of the total share capital of the Company)	48.39%	48.83%	48.39%	48.83%	

Contd.....2



**Notes:**

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 07.05.2010.
- 2 The Company is primarily engaged in a single segment business of Manufacturing & Marketing of Pharmaceutical Formulations and Active Pharmaceutical Ingredients and is managed as one entity, for its various activities and is governed by similar set of risk and returns.
- 3 The Company has issued and allotted 1333 equity shares of Re. 1 each on conversion of one FCCB of US\$1000 on 14.4.2010. Accordingly the issued, Subscribed and Paid up equity share capital of the company has increased from Rs.367805871/- to Rs.367807204/- effective from 14.4.2010.
- 4 During the year, The Company received an assessment order from the Income Tax Department for the A.Y 2002-03 to A.Y 2008-09 along with demand for Rs.450 lacs. The Company has gone into Appeal before the Commissioner of Income Tax (Appeals) against the said assessment order after making tax payment of Rs.200 lacs under protest. According to the expert advise, the Company has a good case therefore, no provision has been made in the books of accounts but shown as Contingent Liability.
- 5 No Provision have been made during the year for Foreign Exchange Difference account in case of Foreign Currency Convertible Bond. The Management is of the opinion that the determination and crystallisation of liabilities is dependent upon the outcome of uncertain future events or actions, not wholly within the control of the company and therefore the same has been considered as a "Contingent Liability" as at 31st March, 2010
- 6 There were no pending investor complaints at the beginning & end of the Quarter. The Company has not received any investors complaint during the quarter.
- 7 Previous year's figures have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current year's figures.

FOR MARKSANS PHARMA LTD

  
**MARK SALDHANA**  
 Managing Director



Place: Mumbai.

Date: May 07, 2010.

Visit us at [www.marksanspharma.com](http://www.marksanspharma.com)

4/6

**MARKSANS PHARMA LIMITED**


Regd. Office: 21st Floor, Lotus Business Park Off. New Link Road, Andheri West, Mumbai-400053

**UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 31st March 2010**

Rs. In Lacs

Sr. No.	PARTICULARS	For the Quarter ended on		For the year ended on	
		31.3.2010 (UNAUDITED)	31.3.2009 (UNAUDITED)	31.3.2010 (UNAUDITED)	31.3.2009 (AUDITED)
1	Income				
a>	Net Sales/ Income from Operations	9,631.88	6,840.42	36,310.17	36,013.10
b>	Other Operating Income	157.07	450.59	314.53	806.40
	<b>Total Income</b>	<b>9,788.95</b>	<b>7,291.11</b>	<b>36,624.70</b>	<b>36,819.50</b>
2	Expenditure				
a>	(Increase)/Decrease in stock in trade	(291.89)	(754.18)	1,200.09	(859.69)
b>	Consumption of Material & Purchases	6,685.04	5,754.27	24,235.47	25,151.46
c>	Employee Cost	1,042.06	1,422.82	3,678.74	3,737.21
d>	Depreciation	360.30	694.58	1,371.86	1,535.45
e>	Other Expenditure	1,132.90	2,502.68	4,395.14	5,819.05
	<b>Total Expenditure</b>	<b>8,928.42</b>	<b>9,620.17</b>	<b>34,881.29</b>	<b>35,383.48</b>
3	Profit from Operations before other income				
	Interest & Exceptional Items (1-2)	860.54	(2,329.06)	1,743.42	1,436.02
4	Other Income				
5	Profit before Interest & Exceptional Item (3+4)	860.54	(2,329.06)	1,743.42	1,436.02
6	Interest	565.43	585.93	2,294.22	2,135.94
7	Profit after Interest but before Tax Exceptional Items	295.11	(2,914.99)	(550.80)	(699.92)
8	Exceptional Items				
9	Profit/(Loss) from Ordinary activities before Tax (7+8)	295.11	(2,914.99)	(550.80)	(699.92)
10	Tax Expenses - Earlier year Income tax	48.94	(160.96)	81.19	95.57
11	Net Profit/(Loss) from Ordinary activities after tax(9-10)	246.17	(2,754.03)	(631.99)	(795.49)
12	Extraordinary Item - Minority Interest	17.69	(75.57)	42.89	40.05
13	Net Profit/ (Loss) for the period (11-12)	228.47	(2,678.46)	(674.89)	(835.54)
14	Paid up Equity Share Capital (Face Value Re. 1 each)	3,678.05	3,678.05	3,678.05	3,678.05
15	Reserve Excluding Revaluation Reserve as per Balance sheet of Previous Accounting Year	-	-	-	10,000.66
16	a> Earnings Per Share (Basic & Diluted)	0.07	(0.75)	(0.17)	(0.22)
	(before extraordinary items Re.)				
	b> Earnings Per Share( Basic & Diluted) (after Extraordinary items- Rs.)	0.06	(0.73)	(0.18)	(0.23)
17	Aggregate of Public Shareholding:				
	- Number of Shares	189,822,361.00	188,222,361.00	189,822,361.00	188,222,361.00
	- Percentage of Holding	51.61%	51.17%	51.61%	51.17%
18	Promoters and Promoter group Shareholdings				
a>	Pledged/Encumbered	177,983,510.00	179,583,510.00	177,983,510.00	179,583,510.00
	- Number of Shares	NIL	NIL	NIL	NIL
	- Percentage of Holding (as a % of the total shareholding of Promoter and Promoter Group)	N/A	N/A	N/A	N/A
	- Percentage of Holding (as a % of the total share capital of the Company)	-	-	-	-
a>	Non-encumbered	177,983,510.00	179,583,510.00	177,983,510.00	179,583,510.00
	- Number of Shares	100%	100%	100%	100%
	- Percentage of Holding (as a % of the total shareholding of Promoter and Promoter Group)	48.39%	48.83%	48.39%	48.83%
	- Percentage of Holding (as a % of the total share capital of the Company)	-	-	-	-

Contd.....2



9/5

	For the Quarter ended on	31.3.2010	31.3.2009	31.3.2010	31.3.2009
		31.3.2010	31.3.2009	31.3.2010	31.3.2009
	(UNAUDITED)	(UNAUDITED)	(UNAUDITED)	(UNAUDITED)	(AUDITED)
<b>Standalone Information (Un audited)</b>					
Revenue	6,711.70	3,653.97	20,703.00	21,091.16	
Profit Before Tax	540.99	(1,367.88)	55.63	239.08	
Profit After Tax	507.49	(1,343.13)	22.13	49.50	

**Notes:**

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 07.05.2010.
- 2 The Company is primarily engaged in a single segment business of Manufacturing & Marketing of Pharmaceutical Formulations and Active Pharmaceutical Ingredients and is managed as one entity, for its various activities and is governed by similar set of risk and returns.
- 3 The Company has issued and allotted 1333 equity shares of Re.1 each on conversion of one FCCB of US\$1000 on 14.4.2010. Accordingly the Issued, Subscribed and Paid up equity share capital of the company has increased from Rs.367905974/- to Rs.367907204/- effective from 14.4.2010.
- 4 During the year, The Company received an assessment order from the Income Tax Department for the A.Y 2002-03 to A.Y 2008-09 along with demand for Rs.450 lacs. The Company has gone into Appeal before the Commissioner of Income Tax (Appeals) against the said assessment order after making tax payment of Rs.200 lacs under protest. According to the expert advise, the Company has a good case therefore, no provision has been made in the books of accounts but shown as Contingent Liability.
- 5 No Provision have been made during the year for Foreign Exchange Difference account in respect of Foreign Currency Convertible Bond. The Management is of the opinion that the determination and crystallisation of liabilities is dependent upon the outcome of uncertain future events or actions, not wholly within the control of the Company and therefore, the same has been considered as "Contingent Liability" as at 31st March,2010.
- 6 The Consolidated Financial Statements Include Financial Statements of the subsidiaries Nova Pharmaceuticals Australasia Pty Ltd and Marksans Pharma (U.K.) Limited.
- 7 Marksans Pharma (U.K.) Ltd, a subsidiary of Marksans Pharma Ltd, acquired Relonchem Limited on 27.8.2008 Therefore, to that extent the corresponding results of previous year are not comparable.
- 8 The Consolidated Financial Statements are prepared in accordance with Accounting Standard 21 "Consolidated Financial Statement" issued by the Institute of Chartered Accountants of India.
- 9 There were no pending investor complaints at the beginning & end of the Quarter. The Company has not received any investors complaint during the quarter.
- 10 Previous year's figures have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current year's figures.

For MARKSANS PHARMA LTD

MARK SALDHANA  
Managing Director



Place: Mumbai.  
Date: May 7, 2010.  
Visit us at www.marksanspharma.com